An interventional study of Motion in PKU, Phenylketonurias and Inborn Errors of Metabolism, sponsored by Dr. Schär AG / SPA. Completed at 1 site in United Kingdom. Open to participants aged 3 Years to 16 Years. Per ClinicalTrials.gov, last updated 2020-03-16.
Sponsored by Dr. Schär AG / SPA · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Phenylketonurias with a site in United Kingdom — 7 open to participants now, 8 under way, 1 of them phase 3. Phenylketonurias · United Kingdom.
Among the 35 studies in Phenylketonurias with a site in United Kingdom, this one is the 22nd largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2018, is one of 20 with no phase, and was the 15th registered.
191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.
Browse Phenylketonurias studies →7 of the 35 studies in Phenylketonurias with a site in United Kingdom are open now. Recruiting first, the newest first:
Maze Therapeutics · Sites in United Kingdom, United States, France
Ages 18–75
Birmingham Women's and Children's NHS Foundation Trust · Sites in United Kingdom
Ages 3–17 · Healthy volunteers
Nutricia UK Ltd · Sites in United Kingdom
Ages 3+
PTC Therapeutics · Sites in United Kingdom, United States, Australia and 4 more countries
Ages up to 9
Egoo Health Aps · Sites in United Kingdom
Ages up to 3
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.
This study: 3 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 4 · Phase 4 1
First in 2009; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 27 across 122 interventional studies indexed under Phenylketonurias.
Median enrollment 20 across the 27 interventional studies, 29 across the 8 observational. Of the 24 that completed or were terminated, 3 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 35 have an industry lead sponsor. The 10 most frequent:
Dr. Schär AG / SPA is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Dr. Schär AG / SPA has 2 studies filed under Phenylketonurias — fewer than ten, so there is no comparison to draw.
4 of the studies in Phenylketonurias with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07728032Birmingham Women's and Children's NHS Foundation TrustImpact Of A Phe-Restricted Diet On Gut Health In Children With PKU | 2026-12 |
| NCT06941532Nutricia UK LtdGMP Powdered Substitutes in PKU and TYR | 2026-12-31 |
| NCT07802366metaX Institut fuer Diatetik GmbHMarket Research of a Slow Release Protein Substitute for the Dietary Management of PKU | 2027-05-01 |
| NCT07671859Nutricia UK LtdPKU Microtablets Case Studies | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 35 studies in Phenylketonurias with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to demonstrate that a new protein substitute is acceptable and well tolerated in children with PKU.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
amino acid based protein substitute
Dietary Supplement: Motion
Amino acid based protein substitute
Gastrointestinal tolerance
Questionnaire detailing any GI symptoms, severity and change from usual • The collection of daily data about the gastro-intestinal tolerance of the protein substitute.
Time frame: 7 days
Product compliance
Daily questionnaire on amounts offered and amounts actually consumed, compared to recommended amount.
Time frame: 7 days
Product palatability
Questionnaire data captured to evaluate taste
Time frame: 7 days
Product acceptability
Brief tick-box questionnaire on overall liking and acceptability of product
Time frame: 7 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2018 to primary completion in Sep 2018, 2 months.
Of 33 interventional studies with no phase under Phenylketonurias, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 28. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr. Schär AG / SPA